Orisdx
Chicago, US · Founded 2022 · Delaware corporation · 9 employees on LinkedIn · 2 known investors
OrisDX develops a non-invasive salivary-rinse DNA test called Oro Lesion to detect early markers of oral cavity squamous cell carcinoma in adults with indeterminate oral lesions. It pairs the test with Oris Bridge, a digital health patient navigator that handles clinical referrals, patient education, and medical claim automation and review.
Founders & leadership
Investors · 2
Reported raises · per SEC filings
Form D private placements$2.8M disclosed across 1 round · 2025
▶$2.8MraisedJul 2025 · 25 investors · BiotechnologyRule 506(b)
▶$2.8MraisedJul 2025 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Harald SteltzerExecutive Officer, Director
- Evgeny IzmchenkoDirector
- Patrick ConniffExecutive Officer
- Nishant AgrawalDirector
- Offering amount
- $4M
- Amount sold
- $2.8M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Orisdx do?
- OrisDX develops a non-invasive salivary-rinse DNA test called Oro Lesion to detect early markers of oral cavity squamous cell carcinoma in adults with indeterminate oral lesions. It pairs the test with Oris Bridge, a digital health patient navigator that handles clinical referrals, patient education, and medical claim automation and review.
- Who are Orisdx's investors?
- Orisdx's investors include Angel Physicians Fund, HARPER COURT VENTURES.
- How much funding has Orisdx raised?
- Orisdx has disclosed $2.8M raised across 1 round.
- Where is Orisdx headquartered?
- Orisdx is headquartered in Chicago, US.